Chengdu SBK Wins Approval for Sichuan Provincial Key R&D Project in 2024

Recently, Sichuan Provincial Department of Science and Technology released the Public Notice on the Second Batch of Provincial Science and Technology Plan Projects for 2024. We are excited to announce that our company’s project, “R&D of Chemical Class 1 New Drug SBK013”, has been approved, with a funding allocation of RMB 500,000. This project marks SBK’s first approved Key R&D Project under the Sichuan Provincial Department of Science and Technology’s programs, representing a major achievement in our journey from “zero to one”. This approval reflects the regulatory recognition of our technological capabilities and the high quality of our project.

//About SBK//
Headquartered in the Chengdu Hi-Tech Industrial Development Zone, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world and dedicated to differentiated drug innovation. We are dedicated to becoming a world leader in the differentiated innovation of novel drugs with a focus on cardiovascular, cerebrovascular, and respiratory therapies. We have built an integrated innovation platform centered on drug metabolism differentiation, supported by 51 proprietary intellectual properties. This platform enables the identification of drugs with metabolic deficiencies and the design of novel molecular structures to address clinical challenges related to metabolic variability—such as individual differences in drug safety and efficacy—ultimately meeting the pressing therapeutic needs of patients.

Looking ahead, we will continue to harness our integrated innovation platform for drug metabolism differentiation to drive technological breakthroughs and develop superior novel therapies that advance global health.